|
Charles River Laboratories International, Inc. (CRL) Valoración de DCF
US | Healthcare | Medical - Diagnostics & Research | NYSE
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Charles River Laboratories International, Inc. (CRL) Bundle
¡Evalúe las perspectivas financieras de Charles River Laboratories International, Inc. (CRL) con precisión experta! Esta calculadora DCF (CRL) proporciona datos financieros preconidos junto con la flexibilidad para modificar el crecimiento de los ingresos, WACC, los márgenes y otros supuestos esenciales para alinearse con sus predicciones.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,621.2 | 2,923.9 | 3,540.2 | 3,976.1 | 4,129.4 | 4,633.1 | 5,198.3 | 5,832.4 | 6,543.9 | 7,342.1 |
| Revenue Growth, % | 0 | 11.55 | 21.08 | 12.31 | 3.86 | 12.2 | 12.2 | 12.2 | 12.2 | 12.2 |
| EBITDA | 581.7 | 759.1 | 854.3 | 1,035.9 | 1,032.1 | 1,142.8 | 1,282.3 | 1,438.7 | 1,614.2 | 1,811.1 |
| EBITDA, % | 22.19 | 25.96 | 24.13 | 26.05 | 24.99 | 24.67 | 24.67 | 24.67 | 24.67 | 24.67 |
| Depreciation | 198.1 | 234.9 | 265.5 | 303.9 | 314.1 | 355.3 | 398.6 | 447.3 | 501.8 | 563.0 |
| Depreciation, % | 7.56 | 8.03 | 7.5 | 7.64 | 7.61 | 7.67 | 7.67 | 7.67 | 7.67 | 7.67 |
| EBIT | 383.6 | 524.2 | 588.8 | 732.0 | 718.0 | 787.6 | 883.6 | 991.4 | 1,112.4 | 1,248.0 |
| EBIT, % | 14.64 | 17.93 | 16.63 | 18.41 | 17.39 | 17 | 17 | 17 | 17 | 17 |
| Total Cash | 238.0 | 228.4 | 241.2 | 233.9 | 276.8 | 336.3 | 377.3 | 423.3 | 475.0 | 532.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 514.0 | 617.7 | 642.9 | 752.4 | 780.4 | 896.2 | 1,005.5 | 1,128.2 | 1,265.8 | 1,420.2 |
| Account Receivables, % | 19.61 | 21.13 | 18.16 | 18.92 | 18.9 | 19.34 | 19.34 | 19.34 | 19.34 | 19.34 |
| Inventories | 160.7 | 185.7 | 199.1 | 255.8 | 380.3 | 312.7 | 350.9 | 393.7 | 441.7 | 495.6 |
| Inventories, % | 6.13 | 6.35 | 5.63 | 6.43 | 9.21 | 6.75 | 6.75 | 6.75 | 6.75 | 6.75 |
| Accounts Payable | 111.5 | 122.5 | 198.1 | 205.9 | 168.9 | 216.0 | 242.3 | 271.9 | 305.1 | 342.3 |
| Accounts Payable, % | 4.25 | 4.19 | 5.6 | 5.18 | 4.09 | 4.66 | 4.66 | 4.66 | 4.66 | 4.66 |
| Capital Expenditure | -140.5 | -166.6 | -228.8 | -324.7 | -318.5 | -309.5 | -347.2 | -389.6 | -437.1 | -490.5 |
| Capital Expenditure, % | -5.36 | -5.7 | -6.46 | -8.17 | -7.71 | -6.68 | -6.68 | -6.68 | -6.68 | -6.68 |
| Tax Rate, % | 18.35 | 18.35 | 18.35 | 18.35 | 18.35 | 18.35 | 18.35 | 18.35 | 18.35 | 18.35 |
| EBITAT | 318.0 | 427.1 | 478.9 | 571.3 | 586.2 | 638.5 | 716.4 | 803.8 | 901.9 | 1,011.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -187.7 | 377.7 | 552.7 | 392.1 | 392.4 | 683.1 | 646.7 | 725.6 | 814.1 | 913.4 |
| WACC, % | 9.19 | 9.17 | 9.17 | 9.13 | 9.17 | 9.17 | 9.17 | 9.17 | 9.17 | 9.17 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 2,888.4 | |||||||||
| Long Term Growth Rate, % | 3.00 | |||||||||
| Free cash flow (T + 1) | 941 | |||||||||
| Terminal Value | 15,255 | |||||||||
| Present Terminal Value | 9,839 | |||||||||
| Enterprise Value | 12,727 | |||||||||
| Net Debt | 2,790 | |||||||||
| Equity Value | 9,938 | |||||||||
| Diluted Shares Outstanding, MM | 51 | |||||||||
| Equity Value Per Share | 193.15 |
What You Will Get
- Real CRL Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Charles River Laboratories International, Inc. (CRL).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates to fit your analysis needs.
- Instant Valuation Updates: Automatic recalculations to assess the impact of changes on CRL’s fair value.
- Versatile Excel Template: Designed for quick edits, scenario testing, and comprehensive projections.
- Time-Saving and Accurate: Avoid the hassle of building models from scratch while ensuring precision and flexibility.
Key Features
- Comprehensive Historical Data: Access to Charles River Laboratories' (CRL) past financial statements and projected forecasts.
- Customizable Inputs: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Valuation: Watch the intrinsic value of Charles River Laboratories (CRL) update instantly.
- Intuitive Visual Representations: Dashboard graphs showcase valuation outcomes and essential metrics.
- Designed for Precision: A reliable tool tailored for analysts, investors, and finance professionals.
How It Works
- Download: Access the ready-to-use Excel file with Charles River Laboratories' (CRL) financial data.
- Customize: Adjust forecasts, including revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations update in real-time.
- Test Scenarios: Create multiple projections and compare outcomes instantly.
- Make Decisions: Use the valuation results to guide your investment strategy.
Why Choose This Calculator?
- Accurate Data: Real Charles River Laboratories International, Inc. (CRL) financials ensure reliable valuation results.
- Customizable: Adjust key parameters like growth rates, WACC, and tax rates to match your projections.
- Time-Saving: Pre-built calculations eliminate the need to start from scratch.
- Professional-Grade Tool: Designed for investors, analysts, and consultants.
- User-Friendly: Intuitive layout and step-by-step instructions make it easy for all users.
Who Should Use This Product?
- Investors: Accurately assess the fair value of Charles River Laboratories International, Inc. (CRL) before making investment decisions.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to CRL.
- Consultants: Easily customize the template for valuation reports tailored to clients interested in CRL.
- Entrepreneurs: Discover insights into financial modeling practices employed by leading firms like Charles River Laboratories (CRL).
- Educators: Implement it as a teaching resource to illustrate valuation methodologies relevant to CRL.
What the Template Contains
- Pre-Filled DCF Model: Charles River Laboratories' (CRL) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Charles River Laboratories' (CRL) profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.